(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage ...

AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...

Shares of AbbVie (ABBV) were in the spotlight on Wednesday after the company announced positive results from a late-stage ...

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Bavarian Nordic has sold a PRV for $160m, a day after the FDA announced a new scheme utilising the fast-track tickets.

President Trump has threatened to impose pharma tariffs to encourage investment in U.S. manufacturing, but experts say there could be unintended consequences.